Send to

Choose Destination
Curr Hematol Malig Rep. 2012 Jun;7(2):94-102. doi: 10.1007/s11899-012-0119-0.

Genomic instability in chronic myeloid leukemia: targets for therapy?

Author information

Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD 21230, USA.


Philadelphia positive (Ph+) chronic myeloid leukemia (CML) is characterized by the occurrence of nonrandom genetic and cytogenetic abnormalities during disease progression. Many of these abnormalities are markers for genes which, when altered, can drive the blastic transformation process. Thus, such genetic alterations may be manifestations of an underlying genomic instability resulting from a compromised DNA damage and repair response, leading to advanced stages of CML and resistance to therapy. This article examines the molecular pathways that may lead to genomic instability in CML and the potential of these pathway constituents to be therapeutic targets.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center